On this occasion, we want to delve into the fascinating world of Timeline of immunology. Whether you are interested in learning more about its history, understanding its importance in today's society or simply exploring its many applications, this article is designed to offer you a deep and complete insight into the topic. Through extensive analysis and careful research, we aim to provide you with relevant and up-to-date information that helps you better understand Timeline of immunology and its impact on the world around us. No matter your level of prior knowledge on the topic, we hope you find this article informative, entertaining, and educational. Join us on this journey of discovery and learning about Timeline of immunology!
The following are notable events in the Timeline of immunology:
1550 BCE – The Ebers papyrus recommends placing a poultice on a tumor and then making an incision, which would induce infection and cause regression of the tumor.
1829 – Another case of spontaneous remission of breast cancer after a patient refused surgery and the tumor ruptured, became infected and during a febrile illness with purulent discharge, it shrunk and disappeared after a few weeks. (Guillaume Dupuytren)
1837 – Description of the role of microbes in putrefaction and fermentation (Theodore Schwann)
1838 – Confirmation of the role of yeast in fermentation of sugar to alcohol (Charles Cagniard-Latour)
1850 – Demonstration of the contagious nature of puerperal fever (childbed fever) (Ignaz Semmelweis)
1857–1870 – Confirmation of the role of microbes in fermentation (Louis Pasteur)
1867 – Aseptic practice in surgery using carbolic acid (Joseph Lister)
1868 – Busch discovered that a sarcoma patient being surgically intervened to remove the tumor, after being exposed to a patient suffering from erysipelas, got a skin infection and her tumor disappeared. He inoculated some other cancer patients with many successes.
1876 – Demonstration that microbes can cause disease-anthrax (Robert Koch)
1878 – Confirmation and popularization of the germ theory of disease (Louis Pasteur)
1880 – 81 Theory that bacterial virulence could be attenuated by culture in vitro and used as vaccines. Used to make chicken cholera and anthrax "vaccines" (Louis Pasteur)
1882 – Identification of Streptococcus pyogenes as the causative agent of erysipelas (Friedrich Fehleisen). He repeats Busch experiments inoculating cancer patients with eryisipelas, noting tumor regression in many of them.
1883–1905 – Cellular theory of immunity via phagocytosis by macrophages and microphages (polymorhonuclear leukocytes) (Elie Metchnikoff)
1885 – Introduction of concept of a "therapeutic vaccination". Report of a live "attenuated" vaccine for rabies (Louis Pasteur and Pierre Paul Émile Roux).
2010 – The first autologous cell-based cancer vaccine, Provenge, is approved by the FDA for the treatment of metastatic, asymptomatic stage IV prostate cancer.
2010 – First immune checkpoint inhibitor, ipilimumab (anti-CTLA-4), is approved by the FDA for treatment of stage IV melanoma
2011 – Carl H. June reports first successful use of CAR T-cells expressing the 4-1BB costimulatory signaling domain for the treatment of CD19+ malignancies
2014 – A second class of immune checkpoint inhibitor (anti-PD-1) is approved by the FDA for the treatment of melanoma. Pembrolizumab and nivolumab are approved within months of each other.
2016 – The role of dendritic cell expressed CTLA-4 in Th immune polarization is first described
2016 – A third class of immune checkpoint inhibitor, anti-PD-L1 (atezolizumab), is approved for the treatment of bladder cancer
2017 – First autologous CAR T-cell therapy tisagenlecleucel approved for the treatment of pediatric B-ALL; second autologous CAR T-cell therapy axicabtagene ciloleucel (Yescarta) is approved.
2020 – The first mRNA vaccines (BNT162b2, mRNA-1273), are developed for SARS-CoV-2 infection; this new technology completed design, testing, and emergency approval in under one year.
^Hoption Cann SA, van Netten JP, van Netten C (1 January 2006). "Acute infections as a means of cancer prevention: opposing effects to chronic infections?". Cancer Detection and Prevention. 30 (1): 83–93. doi:10.1016/j.cdp.2005.11.001. PMID16490323.
^Dupuytren G. "De la gangrène spontanée générale et partielle des tumeurs cancéreuses du sein". J Hebdom Med. 4.
^Wei MQ, Mengesha A, Good D, Anné J (January 2008). "Bacterial targeted tumour therapy-dawn of a new era". Cancer Letters. 259 (1): 16–27. doi:10.1016/j.canlet.2007.10.034. PMID18063294.